Investor Relations (IR) Questions: PDL BioPharma PDLI
Click here to return to the biotech IRQ Index
Answers received: February 2013
1) When is the last time PDLI raised cash through an offering (diluted)?
2000 in which it sold 3.45 million shares at approximately $100/share
2) How much cash (not cash equivalents) does PDLI have?
$136.2 million as of the end 3Q12 in cash and cash equivalents – we do not break cash out separately
3) What and approximately when is the next known catalyst?
PDL does not conduct R&D or commercialize any products itself. The next product-related event is the PDUFA date of February 26, 2013 for Genentech's T-DM1 which is licensed under the Queen et al patents
4) What is PDLI's quarterly cash burn?
Approximately $5-6 million cash burn per quarter
5) Does PDLI have an existing line of credit and if so how much can they draw against it?
There is no line of credit.
1) When is the last time PDLI raised cash through an offering (diluted)?
2000 in which it sold 3.45 million shares at approximately $100/share
2) How much cash (not cash equivalents) does PDLI have?
$136.2 million as of the end 3Q12 in cash and cash equivalents – we do not break cash out separately
3) What and approximately when is the next known catalyst?
PDL does not conduct R&D or commercialize any products itself. The next product-related event is the PDUFA date of February 26, 2013 for Genentech's T-DM1 which is licensed under the Queen et al patents
4) What is PDLI's quarterly cash burn?
Approximately $5-6 million cash burn per quarter
5) Does PDLI have an existing line of credit and if so how much can they draw against it?
There is no line of credit.